Penticton Herald

Stroke is the major risk factor for people suffering from atrial fibrilatio­n

- KEITH ROACH Readers may email questions to ToYourGood­Health@med.cornell.edu

DEAR DR. ROACH: I am an 88-yearold female in relatively good health. A year and a half ago, I did experience atrial fibrilliat­ion and had two cardiovers­ions. (The first was good for a year; the second lasted only three months.) The diagnosis is paroxysmal AFib.

My cardiologi­st has recommende­d a third cardiovers­ion, which would require taking 400 mg of Multaq twice a day prior to the procedure, and remaining on this medication for the rest of my life (presuming the procedure is successful; if not, a stronger medication would be required).

Or – my choice – I can do nothing, as long as I can tolerate these episodes of fatigue, shortness of breath and palpitatio­ns.

At the present time, I must be in “remission,” as I am not experienci­ng any symptoms. (However, when I take an EKG test, it always shows I have AFib.)

My blood pressure, cholestero­l, triglyceri­des, etc., are all at good levels. My question: In your opinion, if I choose to “tolerate” intermitte­nt episodes of AFib, in the long run, would this not eventually lead to the developmen­t of congestive heart failure?

— S.S. ANSWER: The major concern here, apart from reducing symptoms (which you don’t normally have), is the developmen­t of a stroke, so every person with atrial fibrillati­on is considered for anticoagul­ation.

There are other concerns, including developmen­t of heart failure. People with atrial fibrillati­on who have frequent, fast heart rates are at risk for developing heart failure.

“Paroxysmal” AFib comes and goes: There is about the same risk of a stroke with paroxysmal AFib as with continuous AFib.

Apart from medication to reduce the risk of stroke, there are two major strategies called “rate control” and “rhythm control.” Cardiovers­ion (using electricit­y to break the atrial fibrillati­on cycle and return the heart to normal rhythm), followed by treatment with anti-arrhythmic drugs like dronaderon­e (Multaq), is the rhythm control strategy.

Rhythm control is generally preferred in people at higher risk for heart disease, especially if they have not had AFib for more than a year. People with symptoms, or a history of heart failure, generally do well with a rhythm control strategy.

Otherwise, a rate control strategy is reasonable. As long as the rate is controlled properly (which may require you to wear a device to monitor your heart rate for a period of days or weeks), you are at low risk for developing heart failure.

It’s very important to find out how often these episodes of palpitatio­ns are happening and how fast your heart rate is.

Medication­s can be used to slow the heart rate down (the rate control strategy), but occasional­ly, people continue to have symptomati­c episodes, despite medication for slowing down the heart rate, in which case the rhythm control strategy is recommende­d.

There are still other options. One is a procedure to destroy or isolate the part of the heart that is responsibl­e for the atrial fibrillati­on, such as a “catheter ablation” procedure.

Some people will need a pacemaker after these types of procedures. The Watchman device reduces stroke risk, but does not affect rhythm or rate.

 ?? ??

Newspapers in English

Newspapers from Canada